

Audit Review Table					
Western Sky Community Care (Org ID: 395329, Sub ID: 14834, Medicaid, Spec Area: None, Spec Proj: None, Contract Number: None)					
Measurement Year - 2023; Date & Timestamp - 6/3/2024 9:48:15 AM					
This submission is on the stage: Apply Mark Final					
Measure/Data Element	Benefit Offered	Rate	Status	Audit Designation	Comment
<b>Effectiveness of Care</b>					
<b>Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents (WCC)</b>					
<i>BMI percentile (Total)</i>		73.48%	R	R	Reported
<i>Counseling for Nutrition (Total)</i>		63.99%	R	R	Reported
<i>Counseling for Physical Activity (Total)</i>		62.29%	R	R	Reported
<b>Childhood Immunization Status (CIS)</b>					
<i>DTaP</i>		64.23%	R	R	Reported
<i>IPV</i>		81.02%	R	R	Reported
<i>MMR</i>		80.54%	R	R	Reported
<i>HIB</i>		80.29%	R	R	Reported
<i>Hepatitis B</i>		82.00%	R	R	Reported
<i>VZV</i>		79.81%	R	R	Reported
<i>Pneumococcal Conjugate</i>		66.18%	R	R	Reported
<i>Hepatitis A</i>		79.56%	R	R	Reported
<i>Rotavirus</i>		63.02%	R	R	Reported
<i>Influenza</i>		33.09%	R	R	Reported
<i>Combo 3</i>		58.39%	R	R	Reported
<i>Combo 7</i>		47.45%	R	R	Reported
<i>Combo 10</i>		24.33%	R	R	Reported
<b>Immunizations for Adolescents (IMA)</b>					
<i>Meningococcal</i>		82.48%	R	R	Reported
<i>Tdap</i>		83.21%	R	R	Reported
<i>HPV</i>		30.41%	R	R	Reported
<i>Combination 1</i>		81.51%	R	R	Reported
<i>Combination 2</i>		29.68%	R	R	Reported
<b>Lead Screening in Children (LSC)</b>					
<i>Lead Screening in Children</i>		36.22%	R	R	Reported
<b>Cervical Cancer Screening (CCS)</b>					
<i>Cervical Cancer Screening</i>		44.53%	R	R	Reported
<b>Colorectal Cancer Screening (COL)</b>					
<i>(Total)</i>		26.94%	R	R	Reported
<b>Chlamydia Screening in Women (CHL)</b>					
<i>(Total)</i>		51.78%	R	R	Reported
<b>Oral Evaluation, Dental Services (OED)</b>					
	Y				
<i>(0-2)</i>		24.27%	R	R	Reported
<i>(3-5)</i>		58.32%	R	R	Reported
<i>(6-14)</i>		58.97%	R	R	Reported
<i>(15-20)</i>		39.89%	R	R	Reported
<i>(Total)</i>		48.48%	R	R	Reported
<b>Topical Fluoride for Children (TFC)</b>					
<i>(1-2)</i>		7.14%	R	R	Reported
<i>(3-4)</i>		8.59%	R	R	Reported
<i>(Total)</i>		7.82%	R	R	Reported
<b>Appropriate Testing for Pharyngitis (CWP)</b>					
	Y				
<i>(Total)</i>		74.06%	R	R	Reported
<b>Use of Spirometry Testing in the Assessment and Diagnosis of COPD (SPR)</b>					
<i>Use of Spirometry Testing in the Assessment and Diagnosis of COPD</i>		23.86%	R	R	Reported
<b>Pharmacotherapy Management of COPD Exacerbation (PCE)</b>					
	Y				
<i>Systemic Corticosteroid</i>		52.70%	R	R	Reported
<i>Bronchodilator</i>		59.46%	R	R	Reported
<b>Asthma Medication Ratio (AMR)</b>					
	Y				
<i>(Total)</i>		65.85%	R	R	Reported
<b>Controlling High Blood Pressure (CBP)</b>					
<i>Controlling High Blood Pressure</i>		55.23%	R	R	Reported
<b>Persistence of Beta-Blocker Treatment After a Heart Attack (PBH)</b>					
	Y				
<i>Persistence of Beta-Blocker Treatment After a Heart Attack</i>		29.73%	R	R	Reported
<b>Statin Therapy for Patients With Cardiovascular Disease (SPC)</b>					
	Y				
<i>Received Statin Therapy (Total)</i>		59.17%	R	R	Reported
<i>Statin Adherence 80% (Total)</i>		65.00%	R	R	Reported
<b>Cardiac Rehabilitation (CRE)</b>					
<i>Initiation (Total)</i>		1.27%	R	R	Reported
<i>Engagement1 (Total)</i>		1.90%	R	R	Reported

<i>Engagement2 (Total)</i>		0.63%	R	R	Reported
<i>Achievement (Total)</i>		0.00%	R	R	Reported
<b>Hemoglobin A1c Control for Patients With Diabetes (HBD)</b>					
<i>HbA1c Control (&lt;8%)</i>		41.36%	R	R	Reported
<i>Poor HbA1c Control</i>		49.15%	R	R	Reported
<b>Blood Pressure Control for Patients With Diabetes (BPD)</b>					
<i>Blood Pressure Control for Patients With Diabetes</i>		57.91%	R	R	Reported
<b>Eye Exam for Patients With Diabetes (EED)</b>					
<i>Eye Exam for Patients With Diabetes</i>		39.90%	R	R	Reported
<b>Kidney Health Evaluation for Patients With Diabetes (KED)</b>					
<i>(Total)</i>		33.25%	R	R	Reported
<b>Statin Therapy for Patients With Diabetes (SPD)</b>	Y				
<i>Received Statin Therapy</i>		49.19%	R	R	Reported
<i>Statin Adherence 80%</i>		60.53%	R	R	Reported
<b>Diagnosed Mental Health Disorders (DMH)</b>					
<i>(Total)</i>		24.42%	R	R	Reported
<b>Antidepressant Medication Management (AMM)</b>	Y				
<i>Effective Acute Phase Treatment</i>		62.72%	R	R	Reported
<i>Effective Continuation Phase Treatment</i>		45.59%	R	R	Reported
<b>Follow-Up Care for Children Prescribed ADHD Medication (ADD)</b>	Y				
<i>Initiation Phase</i>		50.00%	R	R	Reported
<i>Continuation and Maintenance Phase</i>		66.67%	R	R	Reported
<b>Follow-Up After Hospitalization for Mental Illness (FUH)</b>	Y				
<i>30 days (Total)</i>		57.67%	R	R	Reported
<i>7 days (Total)</i>		31.04%	R	R	Reported
<b>Follow-Up After Emergency Department Visit for Mental Illness (FUM)</b>	Y				
<i>30 days (Total)</i>		47.30%	R	R	Reported
<i>7 days (Total)</i>		30.40%	R	R	Reported
<b>Diagnosed Substance Use Disorders (DSU)</b>					
<i>Alcohol (Total)</i>		4.14%	R	R	Reported
<i>Opioid (Total)</i>		3.22%	R	R	Reported
<i>Other (Total)</i>		4.97%	R	R	Reported
<i>Any (Total)</i>		9.25%	R	R	Reported
<b>Follow-Up After High-Intensity Care for Substance Use Disorder (FU)</b>	Y				
<i>30 days (Total)</i>		45.13%	R	R	Reported
<i>7 Days (Total)</i>		27.69%	R	R	Reported
<b>Follow-Up After Emergency Department Visit for Substance Use (FUA)</b>	Y				
<i>30 days (Total)</i>		33.27%	R	R	Reported
<i>7 days (Total)</i>		21.94%	R	R	Reported
<b>Pharmacotherapy for Opioid Use Disorder (POD)</b>	Y				
<i>(Total)</i>		16.70%	R	R	Reported
<b>Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications (SSD)</b>	Y				
<i>Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications</i>		81.15%	R	R	Reported
<b>Diabetes Monitoring for People With Diabetes and Schizophrenia (SMD)</b>					
<i>Diabetes Monitoring for People With Diabetes and Schizophrenia</i>		49.57%	R	R	Reported
<b>Cardiovascular Monitoring for People With Cardiovascular Disease and Schizophrenia (SMC)</b>					
<i>Cardiovascular Monitoring for People With Cardiovascular Disease and Schizophrenia</i>		50.00%	NA	R	Reported
<b>Adherence to Antipsychotic Medications for Individuals With Schizophrenia (SAA)</b>	Y				
<i>Adherence to Antipsychotic Medications for Individuals With Schizophrenia</i>		54.52%	R	R	Reported
<b>Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM)</b>	Y				
<i>Blood Glucose Testing (Total)</i>		59.79%	R	R	Reported
<i>Cholesterol Testing (Total)</i>		38.08%	R	R	Reported
<i>Blood Glucose and Cholesterol Testing (Total)</i>		36.65%	R	R	Reported
<b>Non-Recommended Cervical Cancer Screening in Adolescent Females (NCS)</b>					
<i>Non-Recommended Cervical Cancer Screening in Adolescent Females</i>		0.44%	R	R	Reported
<b>Appropriate Treatment for Upper Respiratory Infection (URI)</b>	Y				
<i>(Total)</i>		79.20%	R	R	Reported
<b>Avoidance of Antibiotic Treatment for Acute Bronchitis/Bronchiolitis (AAB)</b>	Y				
<i>(Total)</i>		56.48%	R	R	Reported
<b>Use of Imaging Studies for Low Back Pain (LBP)</b>					

	(Total)	69.18%	R	R	Reported
<b>Use of Opioids at High Dosage (HDO)</b>	Y				
	<i>Use of Opioids at High Dosage</i>	2.83%	R	R	Reported
<b>Use of Opioids From Multiple Providers (UOP)</b>	Y				
	<i>Multiple Prescribers</i>	14.00%	R	R	Reported
	<i>Multiple Pharmacies</i>	2.14%	R	R	Reported
	<i>Multiple Prescribers and Multiple Pharmacies</i>	1.30%	R	R	Reported
<b>Risk of Continued Opioid Use (COU)</b>	Y				
	<i>&gt;=15 Days (Total)</i>	2.90%	R	R	Reported
	<i>&gt;=31 Days (Total)</i>	2.23%	R	R	Reported
<b>Access/Availability of Care</b>					
<b>Adults' Access to Preventive/Ambulatory Health Services (AAP)</b>					
	(Total)	65.60%	R	R	Reported
<b>Initiation and Engagement of Substance Use Disorder Treatment (IET)</b>	Y				
	<i>Initiation of SUD Treatment - Total (Total)</i>	44.77%	R	R	Reported
	<i>Engagement of SUD Treatment - Total (Total)</i>	14.80%	R	R	Reported
<b>Prenatal and Postpartum Care (PPC)</b>					
	<i>Timeliness of Prenatal Care</i>	71.78%	R	R	Reported
	<i>Postpartum Care</i>	73.24%	R	R	Reported
<b>Use of First-Line Psychosocial Care for Children and Adolescents on Antipsychotics (APP)</b>	Y				
	(Total)	54.55%	R	R	Reported
<b>Utilization and Risk Adjusted Utilization</b>					
<b>Well-Child Visits in the First 30 Months of Life (W30)</b>					
	<i>(First 15 Months)</i>	58.09%	R	R	Reported
	<i>(15 Months-30 Months)</i>	65.13%	R	R	Reported
<b>Child and Adolescent Well-Care Visits (WCV)</b>					
	(Total)	44.75%	R	R	Reported
<b>Ambulatory Care (AMB)</b>			R	R	Reported
<b>Inpatient Utilization - General Hospital/Acute Care (IPU)</b>			R	R	Reported
<b>Antibiotic Utilization for Respiratory Conditions (AXR)</b>	Y				
	(Total)	28.99%	R	R	Reported
<b>Plan All-Cause Readmissions (PCR)</b>			R	R	Reported
<b>Health Plan Descriptive Information</b>					
<b>Enrollment by Product Line (ENP)</b>			R	R	Reported
<b>Language Diversity of Membership (LDM)</b>			R	R	Reported
<b>Race/Ethnicity Diversity of Membership (RDM)</b>			R	R	Reported
<b>Measures Reported Using Electronic Clinical Data Systems</b>					
<b>Childhood Immunization Status (CIS-E)</b>					
	<i>DTaP</i>		NR	NR	Not Reported
	<i>IPV</i>		NR	NR	Not Reported
	<i>MMR</i>		NR	NR	Not Reported
	<i>HiB</i>		NR	NR	Not Reported
	<i>Hepatitis B</i>		NR	NR	Not Reported
	<i>VZV</i>		NR	NR	Not Reported
	<i>Pneumococcal Conjugate</i>		NR	NR	Not Reported
	<i>Hepatitis A</i>		NR	NR	Not Reported
	<i>Rotavirus</i>		NR	NR	Not Reported
	<i>Influenza</i>		NR	NR	Not Reported
	<i>Combo 3</i>		NR	NR	Not Reported
	<i>Combo 7</i>		NR	NR	Not Reported
	<i>Combo 10</i>		NR	NR	Not Reported
<b>Immunizations for Adolescents (IMA-E)</b>					
	<i>Meningococcal</i>		NR	NR	Not Reported
	<i>Tdap</i>		NR	NR	Not Reported
	<i>HPV</i>		NR	NR	Not Reported
	<i>Combination 1</i>		NR	NR	Not Reported
	<i>Combination 2</i>		NR	NR	Not Reported
<b>Breast Cancer Screening (BCS-E)</b>					

Breast Cancer Screening		37.59%	R	R	Reported
<b>Cervical Cancer Screening (CCS-E)</b>					
Cervical Cancer Screening		38.60%	R	R	Reported
<b>Colorectal Cancer Screening (COL-E)</b>					
(Total)		26.94%	R	R	Reported
<b>Follow-Up Care for Children Prescribed ADHD Medication (ADD-E)</b>					
Initiation Phase			NR	NR	Not Reported
Continuation and Maintenance Phase			NR	NR	Not Reported
<b>Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM-E)</b>					
Blood Glucose Testing (Total)			NR	NR	Not Reported
Cholesterol Testing (Total)			NR	NR	Not Reported
Blood Glucose and Cholesterol Testing (Total)			NR	NR	Not Reported
<b>Depression Screening and Follow-Up for Adolescents and Adults (DSF-E)</b>					
Depression Screening (Total)			NR	NR	Not Reported
Follow-Up on Positive Screen (Total)			NR	NR	Not Reported
<b>Utilization of the PHQ-9 to Monitor Depression Symptoms for Adolescents and Adults (DMS-E)</b>					
Utilization of PHQ-9-Total (Total)			NR	NR	Not Reported
<b>Depression Remission or Response for Adolescents and Adults (DRR-E)</b>					
Follow-Up PHQ-9 (Total)			NR	NR	Not Reported
Depression Remission (Total)			NR	NR	Not Reported
Depression Response (Total)			NR	NR	Not Reported
<b>Unhealthy Alcohol Use Screening and Follow-Up (ASF-E)</b>					
Unhealthy Alcohol Use Screening (Total)			NR	NR	Not Reported
Alcohol Counseling or Other Follow-Up Care (Total)			NR	NR	Not Reported
<b>Adult Immunization Status (AIS-E)</b>					
Influenza (19-65)		14.99%	R	R	Reported
Influenza (66+)		40.02%	R	R	Reported
Influenza (Total)		16.25%	R	R	Reported
Td/Tdap (19-65)		38.47%	R	R	Reported
Td/Tdap (66+)		35.23%	R	R	Reported
Td/Tdap (Total)		38.30%	R	R	Reported
Zoster (50-65)		9.07%	R	R	Reported
Zoster (66+)		25.51%	R	R	Reported
Zoster (Total)		12.22%	R	R	Reported
Pneumococcal (66+)		56.36%	R	R	Reported
<b>Prenatal Immunization Status (PRS-E)</b>					
Influenza		24.84%	R	R	Reported
Tdap		52.51%	R	R	Reported
Combination		20.59%	R	R	Reported
<b>Prenatal Depression Screening and Follow-Up (PND-E)</b>					
Depression Screening			NR	NR	Not Reported
Follow-Up on Positive Screen			NR	NR	Not Reported
<b>Postpartum Depression Screening and Follow-Up (PDS-E)</b>					
Depression Screening			NR	NR	Not Reported
Follow-Up on Positive Screen			NR	NR	Not Reported
<b>Social Need Screening and Intervention (SNS-E)</b>					
Food Screening (Total)		0.00%	R	R	Reported
Food Intervention (Total)			NA	R	Reported
Housing Screening (Total)		0.00%	R	R	Reported
Housing Intervention (Total)			NA	R	Reported
Transportation Screening (Total)		0.00%	R	R	Reported
Transportation Intervention (Total)			NA	R	Reported